Omics TRIZ Cases

Measuring IL-7 and TNF-alpha biomarkers in blood samples replaces complex imaging to reduce testing costs while maintaining high diagnostic accuracy.

PNGase F enzymatic extraction combined with targeted analyte detection improves low-abundance glycan signal-to-noise ratios in tissue imaging.

Amphiphilic copolymers encircle lipid bilayer edges to isolate membrane proteins without detergent-induced aggregation or inactivation.

A serum metabolite panel detects gut flora dysbiosis through specific biomarker concentration measurements.

An organic electrochemical transistor measures conductivity variations in cellular secretomes to identify cancer biomarkers.

Disruptive digestion creates cleavage-site peptides for bottom-up mass spectrometry, resolving throughput limits in complex mixtures.

A monomolecular sensor uses a His-tag binder and fluorophore to detect protein surface changes.

Specific lipid species and ratios identify high-risk coronary artery disease patients beyond traditional cholesterol profiles.

Sample-dependent normalization of stable isotope-labeled peptide transitions controls pre-analytical variability in mass spectrometry.

Biofluid biomarkers and neurophysiological measurements determine a comprehensive disease score for lysosomal storage diseases.

Mass spectrometry quantifies specific lipid amounts in bodily fluids to enable predictive cancer detection models.

Ceramide biomarker detection in plasma samples overcomes low sensitivity of conventional imaging to identify early-stage pancreatic neoplasias.

A metabolomic signature comprising specific biomarkers identifies subjects at risk of acute mesenteric ischemia.

Immunoassays quantify twelve serum proteins to generate a composite risk score for rheumatoid arthritis patients.

An antibody-free method profiles solid tumor peptidomes using tandem mass spectrometry.

Selective labeling and sequential removal overcome Edman degradation limits for complex peptide mixtures.

Peptide arrays detect antibody binding patterns to differentiate scleroderma and dermatomyositis despite similar clinical manifestations.

Changing physicochemical conditions precipitates abundant proteins onto solid particles, reducing dynamic range to detect low-abundance analytes.

Analyzing composite biomarker profiles improves prediction accuracy while maintaining method simplicity, reducing intervention delays.

Experimental detection of modification sites replaces literature inference, resolving data availability limits in cell-type-specific network reconstruction.

A biochemical marker panel detects cardiovascular mortality risk in diabetic subjects using specific protein indicators.

Integrating TOF-SIMS with imaging mass cytometry to map metabolites and proteins at submicron resolution.

Diffusion and Relaxation Editing pulse sequences identify composite N-acetyl glycoprotein signals in plasma samples.

A method for generating blood protein profiles in red blood cell-enriched samples using cationic salts to enhance detection sensitivity.

Analyzing specific sphingolipid ratios overcomes PCR time-dependent sensitivity limits to provide reliable diagnosis across disease stages.

Segmented affinity handles resolve ChIP limitations by enabling comprehensive protein and modification profiling at specific genomic loci.

LC-MS metabolite profiling detects specific biomarkers to resolve diagnostic reliability issues in early stage heart failure.

Comparing endogenous nitrite and nitrate levels against healthy controls allows early detection of chronic valvular disease before clinical symptoms appear.

Pattern analysis of T cell exposed motifs resolves diagnostic accuracy limits by segmenting complex immune data into structured visual comparisons.

Monitoring NNN-trimethyl-5-aminovalerate concentrations detects pre-symptomatic dementia probability, resolving late-stage diagnosis limitations.

Serum peptide patterns identify intracranial hemorrhagic stroke without MRI, resolving the trade-off between diagnostic accuracy and device complexity.

Metabolite biomarkers assess breast cancer using amino acid and lipid ratios, reducing false positives from mammography.

Analyzing plasma metabolite profiles identifies memory impairment risk through comparative assessment against normal values.